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Abstract 
Although the previous trials of inﬂammation have indicated that morin hydrate (MO)hold 
considerable promise, understanding the distinct mechanism of MO against 
inﬂammationremains a challenge.Methods and results: This study investigated the effect of 
MO in atherosclerosis in ApoE−/−mice and underlying cell signaling of MO effect in 
inﬂammation in human umbilical veinendothelial cells (HUVECs). Administration of MO 
signiﬁcantly reduced serum lipid level,inﬂammatory cytokines (TNF-␣ and ICAM-1), and 
atherosclerotic plaque formation in vivo.MO presence attenuated the expression of TNF-␣-
induced inﬂammatory cytokines (ICAM-1,COX-2, and MMP-9), and remarkably enhanced 
microtubule associated protein 1 light chain3 beta 2 (MAP1LC3B2) expression and 
sequestosome 1 (SQSTM1/p62) degradation in HU-VECs. These MO effects were 
signiﬁcantly prevented by the presence of autophagic inhibitors,3-methyladenine (3-MA), or 
chloroquine (CQ), as well as siRNA suppression of ATG5 andBECN1. MO increased 
intracellular cAMP levels and activated cAMP-PKA-AMPK-SIRT1 sig-naling in vivo and in 
vitro. These changes resulted in increased expression of autophagy-relatedprotein 
MAP1LC3B2 and decreased secretion of inﬂammatory cytokines (ICAM-1, COX-2, andMMP-
9).Conclusion: Our results suggest that anti-AS and anti-inﬂammatory effects of MO are 
largelyassociated with its induction of autophagy through stimulation of cAMP-PKA-AMPK-
SIRT1signaling pathway. 
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1. Introduction 
Atherosclerosis is the most common pathological processassociated with serious 
cardiovascular diseases [1], suchas stroke, limb ischemia, and myocardial infarction [2]. 
Accumulating evidence reveal that an inﬂammation process,in which lipid particles and 
immune cells are gradually accu-mulated in subendothelial regions resulting in narrowing 
ofthe arterial lumen and thrombosis, is associated with develop-ment of atherosclerosis [1]. 
This inﬂammation process leadsto endothelial secretion of inﬂammation cytokines and 
otheracute-phase reactants such as IL-1, IL-2, IL-6, IL-8, IL-12, TNF-␣, interferon-␥, and 
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platelet-derived growth factor [3, 4]. Andthese inﬂammation cytokines drive endothelial 
dysfunction,subclinical lesions, the late plaque formation, and disruptionof atherosclerotic 
plaque. Currently, agents directly acting onthe inﬂammatory cascade in atherosclerosis (AS) 
are now in-vestigated widely, raising hope for advances in the treatmentof atherosclerosis. 
Various studies have shown that ﬂavonoids such as morinhydrate (2’, 3, 4’, 5, 7-
pentahydroxyﬂavone) have a good anti-inﬂammatory effect in atherosclerosis [5–7]. Morin 
hydrate(MO) is a bioﬂavonoid isolated as a yellowish pigment fromin a number of fruits, 
vegetables, and herbs of the Moraceaefamily [8]. MO has been reported to exert a variety 
of beneﬁcialpharmacological effects including protection of cardiovascu-lar cells and 
hepatocytes against oxidative injury [5,6], inhibi-tion of xanthine oxidase activity [9], and 
apoptosis inductionhuman colon cancer cells (HCT-116) [10]. MO has also shownto improve 
inﬂammation in human epithelial cells by down-regulating nuclear factor-␥B, mitogen-
activated protein ki-nase signaling pathways, sphingosine kinase 1/sphingosine1-phosphate 
signaling pathway, etc. [11,12]. Recently, severalstudies have shown that autophagy acted 
as a negative reg-ulator of inﬂammation in macrophages [13, 14]. Autophagyis a 
degradation process that delivers cytoplasmic materialsto lysosomes via double-
membraned organelles termed au-tophagosomes (an enclosed portion of the cytoplasm) 
[15].Autophagy, occurring in all cells to maintain mammalianhomeostasis [16], has been 
shown to protect against neu-rodegeneration, inﬂammation in cardiovascular disease 
andcancer [17]. Moreover, autophagy has been reported to con-tribute to the removal of 
misfolded proteins in endothelialcells and prevent the risk of atherosclerosis. The 
presenceof MO has recently been shown to increase the level of in-tracellular cAMP [18], 
one of the most important secondarymessengers and activates PKA in mammalian cells [19, 
20].Activation of cAMP/PKA signaling pathway in endothelialcell is involved in induction of 
autophagy [21]. AMP-activatedprotein kinase (AMPK), a downstream kinase of PKA sig-
naling pathway and an intracellular energy sensor kinase[22], has also been reported to 
regulate autophagy undernormal and stress conditions [23]. AMPK can initiate au-tophagy 
to exert neuroprotection against focal cerebral is-chemia and hence diminish ischemia 
related cell death [24].AMPK was reported to be required for activation of silent in-
formation regulator of transcription 1 (SIRT1) [25] that couldattenuate endothelial 
inﬂammatory reactions by inducing au-tophagy through deacetylation of several autophagy-
relatedgenes [26]. The aim of this study was to evaluate the anti-inﬂammatory effects and 
underlying mechanism of MO invitro in human umbilical vein endothelial cells and in vivo 
inmice. 
2.  Materials and methods 
2.1 Animals 
All animal care and experimental procedures complied withInstitutional Guidelines of 
Animal Care and Use Committeeat Shandong University (Shandong, China). This project 
wasconducted in the School of Pharmacy, Shandong Universityas per the approval granted 
by the Animal Ethics Committeeof Shandong University (NO. ECAESDUSM 201) A total of18 
male 6-week old apolipoprotein E (ApoE)−/−mice and 18male 6-week old C57 mice were 
purchased from Peking Uni-versity Resources Centre (Permission number: SCXK 2011-0012). 
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The animals were maintained in constant temperature-controlled rooms (25 ± 2⬚C) with 
controlled lighting (12 hlight-dark cycle). C57 mice were received normal diet, 
andApoE−/−mice were received a high fat diet (0.25% choles-terol and 15% cocoa butter) 
for 16 weeks. 
2.2 General procedures 
Both the ApoE−/−mice and C57 mice were randomly di-vided into three groups (n = 
6/group): vehicle (2% tween80) group, 30 mg/kg/d and 100 mg/kg/d MO groups. Malemice 
were treated with MO every day via gavage at the doseof 30 mg/kg/d or 100 mg/kg/d for 
ten consecutive weeks.At the end of the experiment, body weight was obtained,and then all 
mice were starved for 12 h and anesthetizedby Urethane. Blood samples were taken from 
the retro-orbital sinus of each mouse into a heparin-containing tube.Serum lipid levels of 
total cholesterol (TC), triglyceride (TG),low-density lipoprotein-cholesterol (LDL-C), and high-
densitylipoprotein-cholesterol (HDL-C) were measured by biochem-istry automatic analyzer 
(Roche Cobas Integra 800, Basel,Switzerland). The concentrations of serum inﬂammatory cy-
tokines (TNF-␣ and ICAM-1) were measured by ELISA kitsaccording to the manufacturer’s 
instructions. Then, all micewere rapidly perfused through the left ventricle with 
PBS,followed by 4% paraformaldehyde. For en face analysis, theaortas from the ascending 
arch to the iliac bifurcation wereprepared and cleaned of peripheral tissue, opened 
longitudi-nally, pinned ﬂat, stained with Oil-Red O and washed by 75%alcohol for 
examination of pathological changes and lipid de-position. Then the areas of the aorta and 
lesions were quan-tized by the software Image pro plus. The ratio of lesion area(R) was 
calculated as R = the areas of lesion aorta/the areas ofall aorta. In addition, aortas tissues 
were lysed in lysis buffer(100 mM Tris-HCl, pH 6.8, 2% m/v SDS, 20% v/v glycerol,200 mM ␤-
mercaptoethanol, 1 mM PMSF, and 1 g/mL apro-tinin) and the expression of proteins (PKA, 
AMPK, p-AMPK,and SIRT1) were determined by Western blotting method 
2.3 Experimental procedures 
2.3.1 Cell culture 
The human umbilical vein endothelial cells (HUVECs) wereisolated from umbilical cord veins 
(Qilu Hospital, Shan-dong University). HUVECs were maintained in endothelialcell medium 
(ECM, ScienCell) supplemented with 5% heat-inactivated fetal bovine serum (FBS), penicillin-
streptomycin(P/S), and endothelial cell growth supplement (ECGS) at 37⬚Cin a humid 
atmosphere (5% CO2–95% air) and were harvestedby brief incubation in 0.25% w/v EDTA-
PBS. All experimentswere conducted with cells within 3–6 passages. 
2.3.2 Cytotoxic assay 
HUVECs (1 × 104per well) were seeded in 96-well plates andcultured till 80–90% conﬂuence 
before introduction of vari-ous concentrations of TNF-␣ (Sigma-Aldrich) (5, 10, 20, 50,100, 
200, and 400 ng/mL) for 4 h. Next, the cells were treatedwith various MO (Sigma-Aldrich) 
concentrations (1, 5, 10,20, 50, 100, 200, and 400 ␥M) for 24 h. The control groupwas 
treated with 0.1% DMSO. After removal of the culturemedium, the cells were washed with 
PBS. Ten percent ofCCK-8 solution (Dojindo, Japan) was then added to the 
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platesfor2hat37⬚C. Light absorbance was measured at 450 nm onThermo Multiskan GO 
microplate reader (Thermo, USA).Triplicate experiments with quintuplicate samples 
wereperformed. 
2.3.3 ELISA assayHUVECs (1 × 104per well) were seeded in 96-well plates andcultured till 
80–90% conﬂuence before exposure to TNF-␣ (5,10, 20, and 50 ng/mL) for 4 h. Some 
groups were pretreatedwith different concentrations of MO (1, 10, and 20 ␥M) for 4 
hbefore exposure to 10 ng/mL TNF-␣ for an additional 4 h. Thelevel of soluble intercellular 
adhesion molecule 1 (sICAM-1)in the culture supernatant was measured using an ELISA 
kit(eBioscience) according to the manufacturer’s instructions.In some experiments, the cells 
were stimulated with orwithout 10 ␥M MO for 4 h, followed by additional 4 h in-cubation 
with or without 10 ng/mL TNF-␣. Cells were thentreated with 10 ␥M KH7 (Cayman) (an 
inhibitor of ADCY)for 1 h or 10 ␥M Rolipram (Selleckchem) (an inhibitor ofPDE4) for 1 h. 
Intracellular levels of cAMP in HUVECs andatherosclerotic plaques were measured also by 
an ELISA kit(R&D systems) according to the manufacturer’s instructions. 
2.3.4 Western blot 
HUVECs (5 × 105per well) were seeded in 6-well platesand exposed to increasing 
concentrations of TNF-␣ (5, 10, 20, and 50 ng/mL) or MO (1, 10, and 20 ␥M) for 4 hand 
then treated with 10 ng/mL TNF-␣ for 4 h. The con-trol group was treated with 0.1% 
DMSO. The cells werethen treated with 3 ␥M CQ (Sigma-Aldrich), 5 mM 3-MA(Sigma-
Aldrich), 5 mM Nicotinamide (Beyotime Biotechnol-ogy,China),2␥M EX527 (Sigma-Aldrich), 
10 ␥MKH7,or10 ␥M Rolipram for 2 h. The cells were then treated withor without TNF-␣ (10 
ng/mL) for another 4 h. Target pro-teins were detected using 1:1000-diluted primary 
antibodiesagainst ICAM-1 (ZhongshanJinqiao Biotechnology, China),COX-2 (Cell Signaling 
Technology), MMP-9 (Cell Signal-ing Technology), MAP1LC3B (microtubule associated pro-
tein 1 light chain 3 beta 2) (Sigma-Aldrich), SQSTM1/p62 (se-questosome 1) (Cell Signaling 
Technology), BECN1 (Cell Sig-naling Technology), ATG5 (Epitomics, USA), PKA 
(WuhanHuamei biotech, China), p-AMPK (Wuhan Huamei biotech,China), AMPK (Wuhan 
Huamei biotech, China), and SIRT1(Cell Signaling Technology). Immunoblots were 
developedusing horseradish peroxidase-conjugated secondary antibod-ies, and visualized 
using an enhanced chemiluminescencereagent (Amersham Pharmacia Biotech) and 
quantiﬁed bydensitometry using a ChemiDoc XRS (Bio-Rad, Berkeley, Cal-ifornia, USA). The 
data are expressed as the relative densityof the protein normalized to ␤-actin. Triplicate 
experimentswith triplicate samples were performed. 
2.3.5 Laser scanning confocal microscopy analysisHUVECs (5 × 104per well) were seeded in 
12-well plates andthen exposed to the various treatments with TNF-␣ or MO.The cells were 
washed twice with fresh medium and loadedwith 100 nM LTG (Invitrogen) for 1 h in 
humidiﬁed air at37⬚C in ECM culture medium. After three washes with PBS,the cells were 
examined using a Radiance 2000 laser scanningconfocal microscope (Nikon, Japan). 
2.3.6 siRNA transfection 
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HUVECs were transfected with 100 nM siRNAs for ATG5or BECN1 (GenePharma, China) for 8 
h according to themanufacturer’s protocol. Cell culture was then switched toECM medium 
for an additional 24 h before treatment ofthe cells with MO (10 ␥M) for 4 h followed by 
exposure to10 ng/mL of TNF-␣ for another 4 h. The cells were harvestedand analyzed by 
Western blot. 
2.3.7 Statistical analyses 
The data and statistical analysis comply with the recommen-dations on experimental design 
and analysis in pharmacol-ogy. Data was expressed as mean ± SEM for three 
differentdeterminations. For cell culture experiments, all results were repeated 
independently at least three times. Relative protein semi-quantiﬁcation was performed 
using AlphaEaseFC soft-ware (AlphaInnotech, USA). Statistical signiﬁcance was ana-lyzed by 
one-way analysis of variance (ANOVA) followed by Dunnett’s multiple range tests. p < 0.05 
was considered asstatistically signiﬁcant. SPSS 13.0 for Windows (SPSS, Inc.,Chicago, IL). 
 
3 Results 
3.1 MO decreases serum lipid level and attenuatesatherosclerotic plaque formation in 
ApoE−/−mice with high fat dietA 
fter treatment with MO for 10 weeks, no differences of bodyweight of the ApoE−/−mice 
occurred between the treatmentand vehicle mice. Elevation of TG, TC, and LDL levels 
wasobserved in mice with high fat diet. Serum lipid levels ofMO-treated groups shown low 
levels of LDL, TC, TG, andHDL compared with the vehicle group (Table 1). And therewere no 
differences of body weight and plasma lipids in C57mice treated with MO for 10 weeks. The 
relative en facelesion area of the aorta was decreased in both MO-treatedgroups compared 
with the vehicle group, and treatment with100 mg/kg MO showed larger reduction than 
treatment with30 mg/kg MO (Fig. 1A and B). Moreover, there were nosigniﬁcant changes of 
body weight and plasma lipids in C57mice treated with MO for 10 weeks in comparison with 
vehiclegroup (Supporting Information Table 1). 
3.2 MO suppresses the production of inﬂammatorycytokines and increases the protein 
expressionof cAMP-PKA-AMPK-SIRT1 pathway inMO-treated ApoE−/−mice 
To observe the effects of MO on the production of inﬂamma-tory cytokines in serum of 
ApoE−/−mice, the levels of TNF-␣and ICAM-1 were measured. Results showed that the 
levelsof TNF-␣ and ICAM-1 in both MO-treated groups were lowerthan the corresponding 
measurements in the vehicle group(Fig. 1C and D). Moreover, MO increased the cAMP 
levelsin aortas plaques accompanied with upregulation of PKA,p-AMPK, SIRT1 expression 
(Fig. 1E–G). In addition, MO in-creased the expression of microtubule associated protein 
1light chain 3 beta 2 (MAP1LC3B2), an autophagic biomarker(Fig. 1F and G). 
 
3.3 MO suppresses production of inﬂammatorycytokines in TNF-␣ stimulated HUVECs 
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To determine the noncytotoxic concentrations of TNF-␣ andMO to be used in experiment, 
cell viability was determinedafter treatment with different concentrations of TNF-␣ 
andMO. Results showed that TNF-␣ at concentrations of upto 20 ng/mL was tolerated by 
HUVECs without signiﬁcantchange of cell viability (Fig. 2A). When the cells were ex-posed to 
increasing concentration of TNF-␣ (0, 5, 10, 20,50 ng/mL), cell secretion of inﬂammatory 
cytokines includ-ing ICAM-1, MMP-9, and COX-2 signiﬁcantly increased ina concentration-
dependent manner (Fig. 2C). Thus, TNF-␣(10 ng/mL) was used to induce inﬂammation on 
HUVECswith no effect on cell viability. Similarly, MO had no effector lower inhibition on cell 
viability at lower concentrations(less than 20 ␥M) compared with 0.1% DMSO group 
(controlgroup) (Fig. 2B, Supporting Information Fig. 1). Preincuba-tion of the cells with MO 
(1, 10, and 20 ␥M) for 4 h before ex-posure to TNF-␣ (10 ng/mL) for 4 h signiﬁcantly 
suppressedthe expressions of ICAM-1, MMP-9, and COX-2, as well assoluble ICAM-1 level, in 
a MO dose-dependent manner incomparison to TNF-␣-treated cells (Fig. 2D–F). 
3.4 MO induces autophagy in both normal HUVECsand TNF-␣ stimulated HUVECs 
The increase of MAP1LC3B2 expression and the decreaseof SQSTM1/P62 expression were 
regarded as autophagicbiomarkers in HUVECs [27]. Chloroquine (CQ), which in-hibits 
autophagosome-lysosome fusion, was used to monitorautophagic ﬂuctuation through 
measuring the protein ex-pression of MAP1LC3B2. Results showed that MO (1, 10,and 20 
␥M) increased the expression of MAP1LC3B2 anddecreased the expression of SQSTM1/p62 
compared withcontrol group in dose- and time-dependent manners. Thepresence of CQ 
showed to induce further accumulation ofMAP1LC3B2 in HUVECs treated with MO (10 ␥M) 
for 4 hcompared with cells treated with CQ alone (Fig. 3A and C).These results revealed that 
MO promoted cellular autophagyin HUVECs, which was suppressed by CQ. 
We found that TNF-␣ treatment had no effect on theexpression of MAP1LC3B and 
SQSTM/p62 compared withcontrol group. Treatment of the cells with MO increasedthe 
expression of MAP1LC3B2 and decreased the expres-sion of SQSTM1/p62 in dose- and time-
dependent manners.In the presence of CQ, the autophagy induction in TNF-␣-stimulated 
HUVECs of MO was also inhibited (Fig. 3B andD). These results suggested that MO induced 
autophagy inboth normal HUVECs and TNF-␣-stimulated HUVECs. 
3.5 The anti-inﬂammatory effects of MO aredependent on autophagy 
LysoTracker Green ﬂuorescent dye (LTG), which stains acidiclysosomes, was used to monitor 
autophagy in MO- and TNF-␣-treated endothelial cells. No signiﬁcant difference of ﬂuo-
rescence intensity was found between TNF-␣ treated and un-treated cells. After treatment 
with MO, however, ﬂuorescenceintensity was dramatically increased relative to cells 
treatedwith TNF-␣ alone, which was suppressed by the presence of 3-methyladenine (3-
MA, an autophagic inhibitor) (Fig. 4Aand C).When TNF-␣-stimulated cells were exposed to 
either5mM3-MAor3␥M CQ, no signiﬁcant difference of theexpression of inﬂammatory 
factors (ICAM-1, MMP-9, andCOX-2) was seen in comparison to the cells treated withTNF-␣ 
alone. MO and TNF-␣ cotreated group decreased theexpression of inﬂammatory factors 
compared with TNF-␣-treated group, which were inhibited by 3-MA and CQ (Fig.4B). In 
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addition, when autophagy was inhibited by siRNAsuppression of ATG5 and BECN1 (the 
essential autophagygenes), the effect of MO on inhibition of the inﬂamma-tory factors was 
notably attenuated (Fig. 4D). siRNA ATG5and BECN1 suppression had no effects on the 
expression ofinﬂammatory factors compared with TNF-␣ treated group.These results 
manifested that autophagy was required for theanti-inﬂammatory effects of MO in HUVECs. 
 
3.6 MO induces autophagy through activatingcAMP-PKA-AMPK-SIRT1 signaling pathway 
inHUVECs 
As shown in Fig. 5A, TNF-␣ stimulation had no effecton cAMP level in HUVECs. However, 
pretreatment of thecells with MO with or without TNF-␣ remarkably increasedcAMP level 
compared with control group. Furthermore, in-troduction of an ADCY inhibitor KH7 to TNF-
␣-treated cells inhibited cAMP production compared with TNF-␣ treatedalone. MO 
presence showed to increase cAMP expressioncompared with KH7 and TNF-␣ cotreated 
group. In addition,introduction of PDE4 inhibitor Rolipram to TNF-␣-treatedcells increased 
cAMP level compared with the TNF-␣ treatedalone, and MO presence further enhanced 
cAMP level com-pared with Rolipram and TNF-␣ cotreated group. Expressionsof PKA, p-
AMPK (phosphorylated AMPK) and SIRT1 levels inHUVECs were increased in response to MO 
single-treatmentin a dose- and time-dependent manner. Similar results wereseen in MO 
and TNF-␣ cotreated cells. However, TNF-␣ treat-ment alone had no signiﬁcant effect on 
the expression ofPKA, p-AMPK, and SIRT1 (Fig. 5B and C). These resultsindicated that MO 
stimulates cAMP-PKA-AMPK-SIRT1 sig-naling pathway by activation of AC and inhibition of 
PDE4 inboth unstimulated and TNF-␣-stimulated HUVECs.To gain further insight into the 
contribution of cAMP-PKA-AMPK-SIRT1 signaling pathway to autophagy inductionand anti-
inﬂammatory effects of MO in HUVECs, SIRT1 in-hibitors, including nicotinamide (VPP) (5 
mM) and EX527(2 mM), were also included in the study. Autophagy in-ductionbyMOonTNF-
␣-treated HUVECs was suppressedsigniﬁcantly by the presence of VPP (Fig 5D and E). 
Mean-while, pretreatment of the cells with VPP or EX527 inhib-ited MO-induced increase of 
MAP1LC3B2 expression andexpression of ICAM-1, COX-2, and MMP-9 (Fig. 5F). Theseresults 
suggested that the anti-inﬂammatory effects of MOwere mainly attributed to induction of 
autophagy throughstimulating cAMP signaling pathway. 
 
4 Discussion 
Atherosclerosis is a chronic inﬂammatory disease [28]. Withthe development of 
atherosclerosis, the accumulation of lipidparticles and cells of the immune system in 
subendothelialregions gradually form lesions corresponds with an inﬂam-mation process 
[3]. And the persistent inﬂammatory stim-ulation induced by interferon-␥,TNF-␣, matrix 
metallopro-teinase or monocyte chemotactic protein-1, eventually leadto degeneration of 
atherosclerosis, including narrowing ofarterial lumen and thrombosis [7]. MO has previously 
beenreported to improve inﬂammation induced by inﬂammatorystimuli in several cell lines 
(epithelial cells, neuronal cells,lung carcinoma cells, and human chondrocytes) [21].In this 
8 
 
study, to investigate the protective effects of MOon AS, a well-established atherosclerotic 
animal model, highfatdietApoE−/−mice were used in vivo [29]. Previous studyhad shown 
that high fat diets could signiﬁcantly increaseTNF-␣ concentration in vivo [30], which is a 
risk factor in AS. Therefore, a TNF-␣-induced inﬂammatory model ofendothelial cells was 
used to investigate the molecular mech-anism of anti-inﬂammation of MO in AS in vitro.In 
vivo, two doses (30 mg/kg, 100 mg/kg) of morin wereused to observe the effectiveness and 
toxicity in mice. Re-sults showed that either low dose or high doses of MOattenuated the 
plaque formation and lipid accumulation in ASmice without signiﬁcant decrease of body 
weight. This indi-cated that the two doses of morin had no signiﬁcant toxicity onmice. 
Through dosage conversion of mice to human [31], the high and low doses in human are 
approximately 7.71 mg/kgand 2.31 mg/kg, respectively, which were modest in compar-ison 
with statins and nonstatins anti-atherosclerosis agentsin clinic [32]. We found that MO 
administration could sig-niﬁcantly decrease serum levels of low-density 
lipoproteincholesterol (LDL-C), total cholesterol (TC), triglycerides (TG)and high-density 
lipoprotein cholesterol (HDL-C), four im-portant independent factors in cardiovascular 
disease. Thedecrease of relative en face lesion area of the aortas was shownin the MO-
treated group, which was consistent with the de-crease of serum lipid levels. Accumulating 
evidence revealsthat lipid molecules inﬂuence the regulatory mechanisms ofinﬂammatory 
reaction that might be mediated by peroxisomeproliferator-activated receptors (PPARs) 
[33]. In the presentstudy, we found that MO signiﬁcantly suppressed the ex-pression of 
inﬂammatory cytokines, TNF-␣ and ICAM-1, inthe serum of MO-treated mice. These results 
suggested that MO had potential anti-inﬂammation and anti-hyperlipidemiaeffects in vivo. 
However, the regulatory mechanisms of itsanti-hyperlipidemia effects need further 
researches. 
In vitro inﬂammation model, MO was seen to regulateTNF-␣-induced inﬂammation by 
inducing autophagy. Au-tophagy, a dynamic process of subcellular degradation, is in-volved 
in the process various diseases such as inﬂammation,cancer, infection, and heart diseases 
[34]. There are strongevidences showing that autophagy protects cells from exces-sive, 
long-lasting inﬂammation by suppressing the forma-tion of proinﬂammatory complexes 
directly and by allowingefﬁcient clearance of damaged organells indirectly [35]. Au-tophagy 
acts as a negative regulator of inﬂammasome forma-tion through integrating a wide range 
of signals of innate im-mune receptors sensing PAMPs or DAMPs (TLRs and NLRs),cytokines 
(IL-1, IL-2, IL-6, TNF-␣,TGF-␤,andIFN-␥) [36], andROS. Impaired autophagy in advanced 
stages of AS, which cases activation of the inﬂammasome, shows to inhibit AS[37]. Our 
results show that MO presence enhances autophagyto protect endothelial cells from the 
action of TNF-␣-inducedinﬂammatory cytokines (ICAM-1, COX-2, and MMP-9). 
Thisdiscovery indicates the possibility that MO might have ther-apeutic value for the 
treatment of inﬂammation-related car-diovascular diseases.We found that MO presence 
increased the cAMP levelsand the expression of cAMP-dependent protein kinase (PKA)in 
endothelial cells. cAMP/PKA signaling pathway is knownto play a critical role in controlling 
autophagy [38–41] andthe presence of dominant-negative form of AMPK, a down-stream 
mediator of PKA signaling, could inhibit autophagy[42]. AMPK is activated by high cAMP 
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level via a mecha-nism involving allosteric regulation, promotion of phospho-rylation by 
AMPK kinase (AMPKK). cAMP/PKA singaling isthought to be involved in stress responses and 
maintenanceof energy homeostasis by attenuation of SIRT1 expression[43]. In this study, 
MO shows to increase the expression ofp-AMPK and SIRT1 in dose- and time-dependent 
manner inendothelial cells and introduction of SIRT1 inhibitors SIRT1,nicotinamide, or 
EX527, reduced autophagy induction andanti-inﬂammatory effects of MO. Consistently, MO 
increasesthe concentration of cAMP and the expression of PKA, p-AMPK, and SIRT1 in aortas 
plaques of ApoE−/−mice. Theseresults suggested that cAMP signaling plays a crucial rolein 
MO-induced autophagy and its anti-inﬂammatory effect(Supporting Information Fig. 2).In 
conclusion, MO reduces serum lipid levels (LDL, HDL,TC, and TG), inﬂammatory cytokines 
(TNF-␣,ICAM-1),and inhibits atherosclerotic plaque development in ApoE−/−mice. MO 
reduces the expression of inﬂammatory cytokines(ICAM-1, COX-2, and MMP-9) in TNF-␣-
stimulated HU-VECs. The anti-inﬂammatory effect of MO is at least partlydependent on 
autophagy induction and is involved in cAMP-PKA-AMPK-SIRT1 signal transduction in vivo 
and in vitro.Thus, the anti-inﬂammatory effect of MO in atherosclerosisis associated with 
autophagy induction through activation ofthe cAMP-PKA-AMPK-SIRT1 signaling.Y.Z. 
performed the research. Y.Z., and X.L.G. designed theresearch study. Z.Q.C., H.Y.W., Y.N.C., 
X.K.Z., and Y.S. con-tributed essential reagents or tools. Y.Z. analyzed the data. Y.Z.,X.L.G., 
and L.G.Y. wrote the paper.This work was funded by the Major Project of Science and Tech-
nology of Shandong Province (2015ZDJS04001) and ShandongProvince Science and 
Technology Key Project (2014GSF118032).The authors declare no conﬂict of interest. 
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